Provenance Record

Tight, well-structured News piece with appropriate Overview / What We Know / What We Don't Know / Analysis sections. Technical depth (trial design, endpoints, CI/HR, safety set) is accurate and clearly attributed.

All 4 snapshots read from disk and verified. source-0.html.gz (CARsgen PRNewswire, 200): confirms June 22 2026 NMPA approval, 'the world's first approved CAR T-cell therapy product for solid tumors', Claudin18.2-positive HER2-negative advanced gastric/GEJ adenocarcinoma, failed at least two prior lines, and Dr. Zonghai Li's full title and exact quote ('an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors'). source-1.html.gz (PubMed 40460847, 200): confirms verbatim the Phase 2 CT041-ST-01 design (156 randomly allocated, n=104 satri-cel / n=52 TPC, 2:1, IRC-assessed PFS primary endpoint), PFS '3·25 months (95% CI 2·86-4·53)' vs '1·77 months (1·61-2·04)', HR '0·37 [95% CI 0·24-0·56]' p<0·0001, CRS 84 (95%) of 88, grade 3+ TEAE 87 (99%) of 88, and the conclusion 'significant improvement in progression-free survival, with a manageable safety profile'. source-2.html.gz (HealthCare MEA, 200): confirms OS 7.92 vs 5.49 months, 'the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication', the Claudin18.2 description 'a protein that is highly expressed in gastric cancers but is limited in normal tissues', and the Dr. Li rollout reporting ('within weeks', 'approximately 200 treatment orders during the second half of 2026'). source-3.html.gz (CARsgen ASCO/Lancet PRNewswire, 200): confirms 'the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors' and the 2025 ASCO / Lancet framing.

Rule 9 applied correctly. Phase 2 trial specifics (156 patients 2:1, PFS 3.25 vs 1.77, HR 0.37, CRS 95% in 84/88, grade 3+ TEAE 99% in 87/88) are cited to the PubMed Lancet Phase 2 abstract that carries them; OS figures (7.92 vs 5.49 months) are cited to HealthCare MEA, the only fetchable source carrying them. CRITICAL CHECK PASSED: the overall-survival hazard ratio (0.693) that appeared only in a search snippet is NOT present in either the PubMed abstract or the HealthCare MEA snapshot, and the article correctly OMITS it — no fabrication. The 'world's first CAR-T for a solid tumor' claim is independently corroborated by 3 sources (CARsgen PR, HealthCare MEA, and PubMed's 'first randomised controlled trial of CAR T-cell therapy in solid tumours globally'). All direct quotes appear verbatim in their cited snapshots.

APPROVE. Every claim, number, quote, name, and date traces verbatim to a cited, snapshotted source. Bot-blocked outlets (OncLive/FiercePharma/Lancet full page) are not cited. The OS HR 0.693 was correctly omitted rather than fabricated. The sole finding is a non-blocking allowlist gap, which does not warrant a corrections record.